Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2022.08.815 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of intensive versus nonintensive antithrombotic treatment on device-related thrombus after left atrial appendage closure.
Rev Esp Cardiol (Engl Ed)
December 2024
Institut Clínic Cardiovascular (ICCV), Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Introduction And Objectives: The optimal antithrombotic therapy (AT) after left atrial appendage closure (LAAC) is debated. We assessed the impact of intensive vs nonintensive AT on the incidence of device-related thrombus (DRT) based on whether the device implantation was classified as optimal or suboptimal.
Methods: This study included patients who underwent successful LAAC in 9 centers.
Impact of Angiographically Detected Residual Trabeculation After Left Atrial Appendage Closure Using the WATCHMAN Device: Insight From the OCEAN-LAAC Registry.
J Cardiovasc Electrophysiol
December 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Background: Research on the impact of angiographically detected residual trabeculation after left atrial appendage closure (LAAC) is limited.
Objectives: To investigate the incidence, characteristics, and clinical implications of angiographically detected residual trabeculation after LAAC using the WATCHMAN device.
Methods: We analyzed 1350 consecutive patients with atrial fibrillation undergoing LAAC using the WATCHMAN device from the OCEAN-LAAC registry, which is a prospective ongoing, multicenter Japanese registry.
5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial.
J Am Coll Cardiol
November 2024
University Hospital of Bern, Bern, Switzerland.
Background: The Amulet IDE trial (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial) evaluated the safety and effectiveness of the Amulet occluder (Abbott) in patients with nonvalvular atrial fibrillation. The Amulet IDE trial is the largest randomized LAAO trial, comparing the Amulet occluder with the Watchman 2.5 device (Boston Scientific).
View Article and Find Full Text PDFImpact of moderate sedation on electrophysiology lab time for left atrial appendage occlusion using 4D-intracardiac echocardiography.
J Cardiovasc Electrophysiol
November 2024
Division of Cardiology, Endeavor Health-North Shore University Health System, Evanston, Illinois, USA.
Article Synopsis
- Left atrial appendage occlusion (LAAO) procedures can be performed using either moderate sedation (MS) or general anesthesia (GA), and this study aimed to compare their effectiveness regarding lab time and complications.
- The study included 135 patients and found that procedures under MS had significantly shorter total lab times (68.3 minutes) compared to GA (117.1 minutes), mainly due to reduced non-procedure time.
- Despite the significant difference in lab time, there were no notable variations in complication rates or overall patient outcomes between the two anesthesia approaches.
Prognostic Impact of Left Atrial Appendage Patency After Device Closure.
Circ Cardiovasc Interv
May 2024
Department of Cardiology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, China.
Background: The prognostic impact of left atrial appendage (LAA) patency, including those with and without visible peri-device leak (PDL), post-LAA closure in patients with atrial fibrillation, remains elusive.
Methods: Patients with atrial fibrillation implanted with the WATCHMAN 2.5 device were prospectively enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!